SPARTANBURG COMMUNITY CLINICAL ONCOLOGY PROGRAM

斯帕坦堡社区临床肿瘤学计划

• 批准号: 2429651
• 负责人: James D Bearden
• 金额: $ 49.21万
• 依托单位: SPARTANBURG REGIONAL MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1983
• 资助国家: 美国
• 起止时间: 1983-09-01 至 2001-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2429651
• 关键词: aspirin; behavioral /social science research tag; breast neoplasms; cancer prevention; cancer rehabilitation /care; chemoprevention; clinical research; colorectal neoplasms; community health services; cooperative study; dietary calcium; early diagnosis; head /neck neoplasm; health science research analysis /evaluation; human morbidity; human mortality; human subject; human therapy evaluation; information dissemination; longitudinal human study; lung neoplasms; neoplasm /cancer diagnosis; neoplasm /cancer education; neoplasm /cancer nutrition therapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer therapy; nutrition related tag; patient care management; prostate neoplasms; quality of life; therapy compliance

Building on 12 years of experience as a CCOP, the Spartanburg Community Clinical Oncology Program (SCCOP) seeks the opportunity to continue to meet our community's need for innovative and relevant studies of promising therapeutic modalities and cancer control research through the Year 2001. The SCCOP provides access to national cooperative clinical trials to nearly a half million people in 6 counties: 3 in South Carolina and 3 in North Carolina. South Carolina is 21st in population density and ranks 14th in the percent who are medically underserved. The service area has a 20% minority base. The regional registry reports over 1,100 new cancer patients per year, an increase of over 158% since 1982. Against this rural background, we developed a three hospital consortium for the conduct of community clinical trials. Unique capacities are demonstrated by the minority accrual over 17% and by the underserved accrual of 84 entries in the last seven years. The SCCOP brings together the strength and resources of a group of multidisciplinary investigators who collaborate in the conduct of studies from SWOG, NSABP, RTOG, and MDACC. The 46 investigators include a single, small, stable, and highly productive practice of 3 hematologists/oncologists along with 41 colleagues in pathology, radiation therapy, surgery, ENT, urology, gastroenterology, as well as internal medicine. The group nearly tripled in size since the early 1990's and together has contributed over 1700 entries to clinical trials since 1983, the start of the CCOP. Over the next five years, the overall aim is to reduce cancer incidence, morbidity, and mortality by accelerating the transfer of newly developed cancer prevention, early detection, treatment, patient management, rehabilitation, and continuing care technology to widespread community application. By careful design, the program will focus over 60% of our resources on cancer control research. These complementary objectives of both treatment and cancer control are a ready match for the patient population and fit within SCCOP interests and capabilities. The immediate goals of the SCCOP are to increase our accrual rate to treatment trials; to maintain wide community participation, including minority groups and underserved populations, in both treatment and cancer control research approved by NCI; and to continue to refine cancer control data management capabilities, including the use of a range of resources to identify potential candidates for cancer control research projects. The continuation of the Breast Cancer Prevention Trial (BCPT), the Prostate Cancer Prevention Trial (PCPT), the Colorectal Prevention Trials, and the upcoming Smoker's Chemoprevention Trial are primary objectives. In summary, the SCCOP track record demonstrates the ability to manage complex clinical research and cancer control activities while producing the highest quality data. The SCCOP has the facilities and well-trained professional personnel to support the full array of studies. The SCCOP staffing pattern, protocol management procedures, patient/participant management approaches, quality control mechanisms, IRS structure and liaison are all in place and functioning to support current and future therapeutic and cancer control activities. Over the next five years, we expect to contribute over 1500 credits to the National Cancer Institute's Community Clinical Oncology Program: over 133 treatment credits and over 183 cancer control credits each year through 2001.

斯巴达堡社区以12年的经验为基础 临床肿瘤学计划（SCCOP）寻求机会继续 满足我们社区对有前途的创新和相关研究的需求 在2001年期间，治疗方式和癌症控制研究。 SCCOP提供了对国家合作临床试验的访问 在6个县中有近50万人：南卡罗来纳州的3人，3个 北卡罗来纳州。 南卡罗来纳州的人口密度是第21位 在医学上服务不足的百分比中第14位。 服务区有 20％的少数民族基础。 区域注册表报告了1,100多个新癌症 每年的患者，自1982年以来增加了158％以上。 农村背景，我们开发了一个三个医院的财团 社区临床试验。 独特的能力由 少数派应超过17％，并在84个条目的应计算 过去七年。 SCCOP汇集了一群的力量和资源 在研究进行合作的多学科研究人员 来自Swog，NSABP，RTOG和MDACC。 46位调查人员包括一个 小型，稳定且高产的实践3 血液学家/肿瘤学家以及41位病理学的同事，辐射 治疗，手术，耳鼻喉科，泌尿外科，胃肠病学以及内部 药品。 自1990年代初以来，该小组的规模几乎增加了两倍 自1983年以来，共同为临床试验贡献了1700多个条目， CCOP的开始。 在接下来的五年中，总体目的是降低癌症的发病率， 发病率和死亡率通过加速新开发 预防癌症，早期检测，治疗，患者管理， 康复和持续护理技术，以广泛的社区 应用。 通过仔细的设计，该计划将集中在我们的60％以上 癌症控制研究的资源。 这些补充目标 治疗和癌症控制都是患者的现成匹配 人口并适合SCCOP的利益和能力。 SCCOP的直接目标是将我们的应计率提高到 治疗试验；维持广泛的社区参与，包括 在治疗和癌症中，少数群体和服务不足的人群 NCI批准的控制研究；并继续完善癌症控制 数据管理功能，包括使用一系列资源来 确定癌症控制研究项目的潜在候选人。 这 继续前列腺预防乳腺癌预防试验（BCPT） 癌症预防试验（PCPT），大肠预防试验和 即将进行的吸烟者的化学预防试验是主要目标。 总而言之，SCCOP记录证明了管理的能力 产生复杂的临床研究和癌症控制活动 最高质量的数据。 SCCOP拥有设施和训练有素的设施 专业人员支持全部研究。 SCCOP 人员配备模式，协议管理程序，患者/参与者 管理方法，质量控制机制，IRS结构和 联络到位，并能够支持当前和未来 治疗和癌症控制活动。 在接下来的五年中，我们预计将为1500多个学分贡献 国家癌症研究所的社区临床肿瘤学计划：超过133 治疗学分和每年超过183个癌症控制学分 2001。